Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
CardioGenics Holdings Inc (CGNH)
Mississauga, ON, CA
CardioGenics Holdings Inc. focuses on the creation and global distribution of diagnostic testing solutions within the in vitro diagnostics (IVD) sector, serving markets across the United States, Canada, Europe, and other international regions. A key offering is the QL Care Analyzer, an automated, self-contained, and portable point-of-care (POC) immunoassay device. This analyzer utilizes a unique, patented self-metering cartridge to perform immunoassay evaluations directly at the point of care. The company also provides a range of immunoassay panels specifically engineered to detect cardiac biomarkers in blood, which is vital for identifying heart attacks. Additionally, CardioGenics supplies paramagnetic beads, serving as crucial solid supports in heterogeneous immunoassay procedures for both clinical and research institutions. Established in 1997, the company was initially known as Jag Media Holdings, Inc. before officially changing its name to CardioGenics Holdings Inc. in 2009. Its corporate headquarters are situated in Mississauga, Canada.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +9,900.00% | +0.00% | +0.00% | -99.92% | -99.00% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Diagnostics & Research: +7.9%—
-
EPS growth Medical - Diagnostics & Research: +30.8%+53.2% ★ Q1'16: +92.3% (vs Q1'15)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%—
-
EBIT margin Medical - Diagnostics & Research: +9.6%—
-
ROIC Medical - Diagnostics & Research: +5.2%— Q1'16: +53.5% (vs Q1'15)
-
Share dilution Medical - Diagnostics & Research: 0.0%+53.0% Q1'16: +57.5% (vs Q1'15)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×-0.10× Q1'16: -0.48× (vs Q1'15)
| Metric |
Oct 2012 actual |
|---|---|
| Revenue |
1.3K
est: 6.78M (-100.0%)
|
| EBITDA |
-1.27M
est: 1.36M (-193.6%)
|
| EBIT |
-1.29M
est: 1.36M (-195.5%)
|
| Net Income |
-1.31M
|
| SGA |
742.0K
est: 985.92M (-99.9%)
|
| EPS |
-0.02
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yahia Abdul Gawad | Founder, Chief Executive Officer & Director | 119.4K | — |
| James A. Essex | Chief Financial Officer | 28.7K | male |
| Linda J. Sterling | Corporate Secretary & Director | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CGNH
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
